MergersCorp M&A International

JULY 5, 2024

The strained relations between the US and China, marked by broad financial sanctions and regulatory scrutiny have made initial public offering and follow on share sales nearly inaccessible for Chinese firms.

Debt 52

Debt Stock Initial Public Offering Capital 52

Cooley M&A

JANUARY 23, 2024

Looming patent cliffs By 2030, more than 190 drugs will lose patent exclusivity , including 69 blockbuster drugs, putting at risk $236 billion in sales. Many buyers have adjusted their valuation expectations across the market accordingly, while the adoption of a “new normal” worldview catches hold more gradually on the sell side.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Software Equity Group

MARCH 21, 2023

Minority investors aim to increase value and earn a return on their investment when your business undergoes additional transactions down the line, whether through additional capital raises, acquisition, or an initial public offering (IPO). You benefit from your investor or buyer’s standing, reputation, and guidance.

Finance 52

Finance Finance Debt Equities 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 30, 2024

a sale, divestiture, change in strategy or management, return of capital to shareholders, etc.). Many of these campaigns agitate for go-privates – arguing that companies are not equipped for the spotlight or expense of being a public company.

Private Equity 52

Private Equity M&A Capital Investors 52

Cooley M&A

JANUARY 25, 2023

However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined private equity sponsor buyers. trillion. [2]

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

NOVEMBER 18, 2024

If you are not aware of the fundamental private equity model, it is simple: buy (or invest in) a company, grow profits through increasing sales, cutting costs and/or add-on acquisitions, and then sell the larger, more profitable company for significantly more than it was purchased for.

Private Equity 52

Private Equity Equities IPO Valuation 52

Cooley M&A

JANUARY 22, 2025

By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales. This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64